Riahi Ryan R, Cohen Philip R
Dermatol Online J. 2011 Feb 15;17(2):15.
Voriconazole is an extended-spectrum triazole antifungal approved for treatment of invasive fungal infections. The drug has been associated with phototoxicity, presenting as photodistributed eruptions such as macular erythema or pseudoporphyria. We describe a 59-year-old man with acute myeloid leukemia, status-post matched unrelated donor stem cell transplant, who developed fungal pneumonia and was placed on posaconazole. The patient had difficulty complying with the four-times daily dosing and was switched to voriconazole 200 mg twice daily. Soon after, the patient began working outside and subsequently developed photodistributed, macular erythema of the head, neck, and upper chest. Melanoma and squamous cell carcinoma have developed in patients with chronic treatment with voriconazole. Strict adherence to photoprotective measures can prevent the side effect of phototoxic eruption or prevent recurrence in patients who develop this adverse reaction without having to discontinue voriconazole.
伏立康唑是一种被批准用于治疗侵袭性真菌感染的广谱三唑类抗真菌药物。该药物与光毒性有关，表现为光分布性皮疹，如斑状红斑或假性卟啉症。我们描述了一名59岁的急性髓系白血病男性患者，在接受匹配的无关供体干细胞移植后，发生了真菌性肺炎并接受泊沙康唑治疗。该患者难以遵守每日四次的给药方案，因此改为每日两次服用200mg伏立康唑。此后不久，患者开始外出工作，随后头部、颈部和上胸部出现了光分布性斑状红斑。长期接受伏立康唑治疗的患者已发生黑色素瘤和鳞状细胞癌。严格遵守光保护措施可以预防光毒性皮疹的副作用，或防止出现这种不良反应的患者复发，而无需停用伏立康唑。
